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recessive MUTYH-associated polyposis (MAP) than in auto-
somal dominant familial adenomatous polyposis (FAP),1 cur-
rent guidelines recommend similar endoscopic surveillance
for both disorders.2–4 This involves gastro-duodenoscopy
starting at 25 to 35 years of age and repeated at intervals
determined by Spigelman staging based on the number, size,
histological type and degree of dysplasia of adenomas, and by
ampullary staging (Supplementary Table 1).
Case reports of duodenal cancers in MAP suggest that they
may develop in the absence of advanced Spigelman stage benign
disease and even without coexisting adenomas.1 Recent molec-
ularanalysessuggest thatMAPduodenaladenomashaveahigher
mutational burden than FAP adenomas and are more likely to
harboroncogenicdrivermutations, suchas those inKRAS.5These
apparent differences in the biology and natural history of
duodenal polyposis in FAP and MAP challenge the assumption
that the same surveillance should be applied in both conditions.
Methods
Study Design and Data Collection
This international multicenter prospective cohort study was
approved by South East Wales NHS Research Ethics Committee
(reference11-WA/0208).Genotypingandendoscopieswerecarried
out as part of routine clinical care (see Supplementary Methods).Contributing centers exported de-identified data to the study data-
base. Only patients with homozygous or compound heterozygous
class 4 or 5 (likely pathogenic/pathogenic) MUTYH variants were
included. All had been enrolled for prospective follow-up and had
undergone at least 1 duodenoscopy. Data collected included the
following: MUTYH genotype; gender; date of birth; dates of endos-
copies; number, size, and histological classification of duodenal and
ampullary polyps (for staging of benign duodenal disease see
Supplementary Table 1); and cancers at each endoscopy.
Statistical Analysis
Median values and ranges are reported for non-normally
distributed data and absolute numbers and percentages for
categorical data. Numbers of polyps in patients with different
genotypes, ages, or gender were compared using 1-way anal-
ysis of variance with Tukey honestly significant difference
correction. Kaplan-Meier analysis was performed for duodenal
polyposis by genotype with censoring at development of
polyps, death or last endoscopy. Statistical analysis was per-
formed using R (version 3.0.2).
Figure 1. Duodenal cancers and adenomas in patients with MAP. (A) Age at diagnosis, gender, genotype and prior Spigelman
stage in four patients with MAP and duodenal cancer. Patient 1: Initial endoscopy showed 3 adenomas, the largest a 4mm
villous adenoma with high grade dysplasia located in the second part of the duodenum. At repeat endoscopy 2 months later
further tubulovillous adenomas with low grade dysplasia were noted. A distally located duodenal adenocarcinoma was
diagnosed at a third endoscopy 12 months later. Patient 2: was reported to be Spigelman stage 0 at initial endoscopy but a
second endoscopy performed 9 months later because of weight loss and anaemia identified a cancer and no background
polyps. Patient 3 presented with abdominal pain and vomiting before duodenal endoscopy had been carried out. At lapa-
rotomy, a 6cm moderately differentiated adenocarcinoma was identified at the duodenal–jejunal flexure. No background
polyps were detected. This patient was reported previously by Nielsen et al8 to have had upper gastrointestinal endoscopy
with normal findings prior to presentation with symptomatic duodenal cancer. However, on reviewing the records this was a
gastroscopy only, without inspection of the duodenum. This patient had therefore developed duodenal cancer prior to in-
clusion in the current study. Patient 4 had an apparently normal initial endoscopy at 82 years of age, but when the procedure
was repeated a year later because of persistent iron deficiency anaemia, a 7cm circumferential tumour at the D2/D3 junction
was detected. (B) Cumulative incidence of duodenal adenomas in MAP by age and genotype. Kaplan-Meier analysis was
performed with patients censored at development of polyps, death or last endoscopy. Y179C homozygotes (Y179C HOM)
were diagnosed with duodenal polyps at a younger age than G396D homozygotes (G396 HOM) or Y179C/G396D compound
heterozygotes, but the differences were not significant.


















The cohort comprised 394 patients. At first duodeno-
scopy, at a median age of 51 years (range 19–92 years), 57
(14.5%) patients aged 37–81 years had adenomas, including
31 of 197 men and 26 of 197 women (P ¼ .45). The median
number of adenomas was 3 (range 1–20). Most were in the
second part of the duodenum and smaller than 10 mm in
diameter. Seven patients had ampullary adenomas. Spigel-
man stage was I in 35 patients (61.4%), II in 11 (19.3%), III
in 10 (17.5%), and IV in 1 (1.8%).
A total of 220 patients underwent 575 further endos-
copies providing 1463 years of prospective follow-up (me-
dian 4 years, mean 6.65 years), during which 38 (21.1%) of
183 previously unaffected patients developed adenomas.
Fourteen (38%) of 37 with initial Spigelman stage I, II, or III
disease who had follow-up progressed to a higher stage
(although some were down-staged again later). The number
with stage IV disease increased from 1 at first endoscopy to
3 at last endoscopy and 3 more progressed to stage IV
during follow-up but were down-staged by endoscopic
intervention. In all, 95 (24.1%) of 394 patients had ade-
nomas detected during the study. Prevalence at last
endoscopy varied from 8 (18%) of 44 in those aged 40 years
or younger to 15 (38%) of 39 in those aged 70 years or
older. The incidence of adenomas varied between centers,
from 1 (5%) of 20 to 22 (38%) of 57, but duration of follow-
up and distribution of genotypes also varied.
Eighteen adenomas with high-grade dysplasia were
identified at first or follow-up endoscopy. Their diameters
ranged from 3 to 25mmand 9 (50%) of 18were smaller than
10 mm. Three patients (1.4%) developed duodenal cancer
during follow-up, and another before inclusion (Figure 1A).
Genotype-Phenotype Relationships
The most frequent pathogenic MUTYH variants were
Y179C and G396D (European ancestry) and E480X (Indian
subcontinent ancestry). Y179C homozygotes were more likely
to have adenomas at initial endoscopy (22/67, 32.8%) than
G396D homozygotes (6/62, 9.7%, P¼ .002) or Y179C/G396D
compound heterozygotes (5/55, 9.1%, P ¼ .003), whereas
E480X homozygotes had an intermediate prevalence of ade-
nomas (7/44, 15.9%). Age-related development of adenomas
by genotype among patients who were unaffected at initial
endoscopy was determined by Kaplan-Meier analysis and
suggested the same genotype-phenotype relationships,
although small numbers precluded further statistical analysis
(Figure 1B). Y179C homozygotes were more likely to have
adenomas with villous components and/or high-grade
dysplasia (8/67, 12%) than were G396D homozygotes (0/
62, 0%, P ¼ .007) or Y179C/G396D compound heterozygotes
(2/55, 4%, P ¼ .11).
Discussion
Duodenal polyposis occurs less frequently inMAP thanFAP,
affecting21.1%ofpatients in our cohort comparedwith65%to
90% in FAP cohorts.6 We found that the risk of duodenal pol-
yposis in MAP depends on genotype, with Y179C homozygotesat increased risk, as found previously for colorectal cancer.7
These genotype-phenotype relationships may reflect differen-
tial effects of mutations on glycosylase activity for DNA repair.
Spigelman stage IV disease occurred rarely in MAP,
reflecting low adenoma burden. Its incidence was 1.5% at a
medianageof55years, comparedwith35%to50%by60years
of age in FAP.6 Although stage IV disease strongly predicts
future cancer in FAP,7 none of the 8 MAP-associated duodenal
cancers reported previously1 or in this study developed in the
context of prior stage IV disease and in 4 no other adenomas
were detected. These observations suggest that Spigelman
staging fails to identify patients with MAP who are at risk of
future cancer. We also noted high-grade dysplasia in small ad-
enomas, suggesting more proactive endoscopic intervention
should be considered in MAP, because current guidelines
recommend resection of adenomas only measuring 10 mm or
larger.4 Two patients developed cancer following apparently
normal endoscopies 9months and 1 year earlier. It is likely that
lesions in these casesweremissed initially. It is also noteworthy
that 3 of the 4 cancers reported here were located in the distal
duodenum. Revision of guidelines for duodenal surveillance
may be required to better prevent duodenal cancer in MAP.
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Supplementary Methods
Identification of Patients With MAP
Patients with MAP were identified from the records of
11 specialist centers in 7 countries (number of patients
identified from each center in parentheses): Milan, Italy
(103); Leiden, the Netherlands (57); Lyon, France (51);
London, United Kingdom (41); Barcelona, Spain (36); Paris,
France (31); Amsterdam, the Netherlands (28); Navarra,
Spain (20); Cardiff, United Kingdom (13); Helsinki; Finland
(9); and Texas, USA (5). Inclusion criteria were (1) a genetic
test result showing homozygosity or compound heterozy-
gosity for clinically actionable (class 4 or 5) variants of
MUTYH according to variant classification in the Leiden
Open Variation Database for MUTYH (https://databases.
lovd.nl/shared/genes/MUTYH); and (2) enrollment to pro-
spective endoscopic surveillance of the duodenum with at
last 1 completed procedure. The criteria may have led to
exclusion of very elderly or unwell patients who were not
offered duodenoscopy, affecting the reported prevalence of
duodenal polyposis.
Several collaborating centers had previously reported
upper gastrointestinal endoscopic findings in some of their
patients,1–3 but none had analyzed findings by genotype. To
optimize power in the present study, patients who had been
included in previous reports were included in the current
study, with updating of data from subsequent follow-up
where available.
Endoscopic and Histopathological Data and
Staging of Benign Disease
Endoscopies were undertaken between December 12,
1986, and December 18, 2017, with most, 893 (92.2%) of
969, being undertaken after January 1, 2000. All were per-
formed as part of routine clinical care following the local
protocols operational at each center. The protocols varied
between centers and over time; for example, in the use of
forward vs side-viewing endoscopes, manufacturer and
model of endoscope, and use of dye-spray (chromoendo-
scopy). Adenoma size was estimated by comparison of the
maximum diameter with the known dimensions of aligned
open biopsy forceps. These variables are expected to influ-
ence polyp detection and staging.4
Histology of adenomas from patients at UK centers was
reviewed by a single experienced gastrointestinal patholo-
gist. Adenomas that had been classified previously as
showing “moderate dysplasia” where, in each case, reclas-
sified to “low grade.” Dysplasia was reported by centers in
other countries as “low grade” or “high grade” and was not
reviewed.
Methods used for staging of duodenal and ampullary
disease are detailed in Supplementary Table 1.
Other Variables, Sources of Bias, and Limitations
We did not collect data on lifestyle factors (such as
smoking and alcohol consumption) or pharmacological
treatments (such as aspirin/nonsteroidal anti-
inflammatory drugs), which could have affected duodenal
polyp burden in this study. As patients were recruited
from specialist hospital centers, the cohort is likely to have
been subject to referral bias. The study did not include a
control group and therefore we could not determine the
efficacy of endoscopic surveillance for prevention of
duodenal cancer.
References
1. Vogt S, et al. Gastroenterol 2009;137:1976–1985.
2. Nielsen M, et al. J Med Genet 2005;42:e54.
3. Walton SJ, et al. Clin Gastroenterol Hepatol 2016;
14:986–992.
4. Hurley JJ, et al. Gastrointest Endosc 2018;88:665–673.
February 2021 Duodenal Polyposis in MAP 954.e1















n % n % n % n %
Y179C_Y179C 67 22 33 28 42 34 51 8 12
G396D_G396D 62 6 10 8 13 29 47 6 10
Y179C_G396D 55 5 9 8 15 31 56 7 13
E480X_E480X 44 7 16 11 25 20 45 3 7
E410GfsX43_E410GfsX43 14 3 21 5 36 13 93 2 14
E480del_E480del 9 0 0 1 11 6 67 2 22
G396D_E410GfsX43 9 0 0 0 0 5 56 0 0
Y179C_E480del 8 0 0 1 13 2 25 1 13
G396D_P405L 7 2 29 2 29 6 86 0 0
Y179C_P405L 6 0 0 5 83 3 50 1 17
Y179C_G264WfsX7 6 1 17 3 50 4 67 2 33
Y179C_A385PfsX23 6 1 17 2 33 2 33 0 0
Y104X_Y104X 6 0 0 0 0 3 50 1 17
G396D_G264WfsX7 5 1 20 1 20 3 60 1 20
Y179C_Q338X 5 0 0 0 0 3 60 0 0
G396D_R245H 5 0 0 1 20 4 80 4 80
G396D_E480del 5 0 0 0 0 1 20 0 0
G396D_A385PfsX23 4 0 0 0 0 2 50 0 0
Y179C_R247X 3 0 0 1 33 1 33 0 0
Y179C_R245H 3 2 67 2 67 2 67 0 0
Y104X_E480del 3 0 0 0 0 2 67 1 33
Y179C_Y104X 3 0 0 0 0 1 33 0 0
Q338X_Q338X 2 0 0 1 50 1 50 1 50
M15V_A385PfsX23 2 0 0 0 0 2 100 1 50
R241W_R241W 2 0 0 0 0 1 50 1 50
Y179C_E410GfsX43 2 0 0 0 0 0 0 0 0
Q391X_Q391X 2 0 0 1 50 1 50 0 0
G189E_G189E 2 0 0 2 100 0 0 0 0
W174X_W174X 2 0 0 0 0 1 50 0 0
R245H_A385PfsX23 2 0 0 1 50 2 100 1 50
Y104X_G264WfsX7 2 0 0 0 0 1 50 1 50
G396D_933þ1delAG 2 1 50 1 50 1 50 1 50
G396D_Q314X 1 0 0 0 0 1 100 0 0
E410GfsX43_E480del 1 1 100 1 100 1 100 0 0
















n % n % n % n %
G396D_L388AfsX143 1 0 0 0 0 1 100 0 0
E479X_E479X 1 0 0 0 0 0 0 0 0
G396D_E479X 1 0 0 0 0 1 100 0 0
Y179C_E196X 1 0 0 0 0 1 100 0 0
G396D_Q338X 1 0 0 0 0 0 0 0 0
Q414X_Q414X 1 0 0 0 0 0 0 0 0
Y104X_Q338X 1 0 0 0 0 1 100 0 0
G396D_M15V 1 0 0 0 0 0 0 0 0
G396D_R368QfsX164 1 0 0 0 0 1 100 0 0
Q414X_Y104C 1 0 0 1 100 0 0 0 0
Y104X_Q414X 1 0 0 1 100 0 0 1 100
G396D_R217H 1 0 0 0 0 0 0 0 0
R247X_P405L 1 0 0 0 0 1 100 0 0
A385PfsX23_P405L 1 0 0 1 100 0 0 0 0
Y179C_V130EfsX98 1 0 0 0 0 0 0 0 0
G396D_R247G 1 0 0 1 100 1 100 0 0
Y179C_V493F 1 1 100 1 100 1 100 0 0
Y179C_E490del 1 1 100 1 100 1 100 0 0
L393fsX_L393fsX 1 0 0 0 0 1 100 0 0
P405L_P405L 1 1 100 1 100 1 100 0 0
Y179C_P430L 1 0 0 0 0 1 100 0 0
V132N_c.924þ3A>C 1 0 0 0 0 1 100 1 100
Q338X_A385PfsX23 1 0 0 0 0 0 0 0 0
c.577–2A>G_c.577–2A>G 1 0 0 0 0 1 100 0 0
R245H_R245H 1 0 0 1 100 0 0 1 100
A385PfsX23_E410GfsX43 1 1 100 1 100 1 100 0 0
G264WfsX7_G264WfsX7 1 0 0 0 0 1 100 0 0
G396D_R182C 1 0 0 0 0 1 100 0 0
G264WfsX7_A385PfsX23 1 0 0 0 0 0 0 0 0
G396D_Y104X 1 0 0 0 0 0 0 0 0
G396D_F432del 1 0 0 1 100 1 100 0 0
G396D_R182L 1 0 0 0 0 0 0 0 0
G396D_A333S346del 1 0 0 0 0 0 0 0 0
933þ1delAG_E480X 1 1 100 1 100 1 100 0 0
















n % n % n % n %
R182H_R182H 1 0 0 1 100 1 100 0 0
R245H_c.349–2A>G 1 0 0 0 0 1 100 1 100
K155E168del_K155E168del 1 0 0 0 0 1 100 0 0
Total 394 57 98 211 49
NOTE. Forty-two different pathogenic MUTYH variants, occurring in 71 different homozygous or compound heterozygous
combinations were reported among the 394 patients. The most commonly identified pathogenic variants were the Y179C and
G396D founder mutations that are frequent in northern Europeans. There were 67 Y179C homozygotes, 61 G396D homo-
zygotes, and 55 Y179C/G396D compound heterozygotes. Forty-four patients were homozygous for the E480X variant that is
commonly found in MAP patients with ancestry from the Indian subcontinent. Other genotypes occurred infrequently, and 29
patients had genotypes that were seen only once.
aColorectal cancers were diagnosed in 211 (54.4%) of 394 patients and other cancers in 49 (12.4%) of 394. These included 9
endometrial cancers and 2 stomach cancers. Fundic gland polyps (FGPs) were not reported in either patient with stomach
cancer, but small numbers of FGPs were reported in some patients. Four patients had 2 or more non-colorectal primary
cancers. Patients who developed non-duodenal cancers were not significantly more likely to have duodenal polyps (58/227,
25.5% vs 37/167, 22.2%) (P > .5).
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